From Our Partners
Tuesday, July 5, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

UGA to Develop New Treatment for Chagas Disease

by Global Biodefense Staff
February 9, 2015

University of Georgia researchers in collaboration with Anacor Pharmaceuticals have received a $5.3 million grant from the Wellcome Trust to develop a new drug for the treatment of Chagas disease, which they hope will be ready to enter clinical trials by 2016.

Chagas disease is caused by the parasite Trypanosoma cruzi, which spreads via a subspecies of blood-feeding insects commonly known as “kissing bugs” because they tend to bite people on the face and lips. While the disease can progress slowly, chronic infection almost inevitably results in irreparable damage to heart and digestive system tissues.

Chagas Kissing Bug Triatoma infestans
Triatoma infestans, the “kissing bug” is a vector for Chagas disease.

Between 10 and 20 million people, mostly in Central and South America, are infected with Trypanosoma cruzi, and Chagas disease kills more people in Latin America than any other infectious disease—including malaria, tuberculosis and HIV. An increasing number of cases are also being documented outside the normal high transmission areas, including in the U.S. and Europe.

“The two drugs commonly used to treat Chagas disease, benznidazole and nifurtimox, require a long course of therapy and have a number of serious side effects,” said Rick Tarleton, UGA Athletic Association Distinguished Research Professor of Biological Sciences in the department of cellular biology in UGA’s Franklin College of Arts and Sciences. “This combined with the fact that many isolates of the parasite are resistant to these existing drugs emphasizes the tremendous need for new treatments.”

Tarleton’s laboratory will work in partnership with Anacor, a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule therapeutics derived from its boron chemistry platform.

Anacor pioneered the development of a boron-based drug class called oxaboroles, which researchers hope will serve as the foundation for a new Chagas therapy.

Boron is a naturally occurring element that is found commonly in fruits, vegetables, milk and coffee, but it is only recently that scientists have begun exploring the potential of boron-containing small molecules in drug development for a variety of infectious agents.

“These new drug classes have a lot of potential for a variety of diseases, including many of the most neglected diseases of humans,” said Tarleton, who is a member of UGA’s Center for Tropical and Emerging Global Diseases. “We have worked with Anacor to identify some potent lead compounds for use in Chagas disease, and this funding will help turn those leads into effective drugs.”

Article courtesy of James Hataway, UGA, edited for context and length.

From Our Partners
Tags: ChagasNeglected Tropical Diseases

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Load More

Latest News

Biodefense Headlines – 5 July 2022

Biodefense Headlines – 5 July 2022

July 5, 2022
Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC